x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011677
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ile121 of human ABHD6 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ABHD6 |
| UniProt No. | Q9BV23 |
| Gene ID | 57406 |
| Gene Description | ABHD6 is a monoacylglycerol lipase, ubiquitously expressed with the highest expression in brown adipose tissue, small intestine, and brain. A high-fat diet upregulates ABHD6 mRNA expression in small intestine and liver, and ABHD6 knockdown protects against high-fat diet-induced obesity, hepatic steatosis, and systemic insulin resistance. In addition, it has been shown that ABHD6 is a negative modulator of glucose-stimulated insulin secretion. In the central nervous system, ABHD6 is expressed postsynptically and degrades the endocannabinoid 2-arachidonoylglycerol, an endogenous activator of cannabinoid receptors. Inhibitors of α/β-hydrolase domain 6 have been actively pursued as a promising approach to treat inflammation, metabolic disorders, and epilepsy. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
